Comparative Pharmacology
Head-to-head clinical analysis: OXYTOCIN 10 USP UNITS IN DEXTROSE 5 versus OXYTOCIN 20 USP UNITS IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYTOCIN 10 USP UNITS IN DEXTROSE 5 versus OXYTOCIN 20 USP UNITS IN DEXTROSE 5.
OXYTOCIN 10 USP UNITS IN DEXTROSE 5% vs OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases intracellular calcium in uterine myofibrils, stimulating contractions. Binds to oxytocin receptors in myometrium and mammary glands.
Oxytocin is a nonapeptide hormone that acts on oxytocin receptors (OXTR) in uterine myometrium and mammary gland epithelium, leading to Gq/11-coupled phospholipase C activation, increasing intracellular Ca2+ and promoting uterine smooth muscle contractions. It also stimulates milk ejection by contracting myoepithelial cells.
IV infusion: 0.5-2 mU/min, increased by 1-2 mU/min every 30-60 min until desired uterine activity, then reduce; max 20 mU/min.
Initial infusion at 0.5-2 mU/min, increased by 1-2 mU/min every 15-30 min until desired uterine activity, then taper. Maximum dose typically 20 mU/min.
None Documented
None Documented
Terminal half-life: 1-6 minutes (IV); clinical effect ceases rapidly after infusion stops due to rapid clearance.
Terminal elimination half-life: 1–6 minutes (IV), with a slower second phase of 12–20 minutes. Clinical context: Rapid clearance necessitates continuous IV infusion for sustained uterotonic effect.
Renal: >99% as unchanged drug; <1% hepatic metabolism and biliary excretion.
Primarily renal (>99% as intact peptide, small amount as metabolites). Biliary/fecal excretion negligible.
Category C
Category C
Oxytocic
Oxytocic